Please login to the form below

Not currently logged in
Email:
Password:

lurasidone

This page shows the latest lurasidone news and features for those working in and with pharma, biotech and healthcare.

EU approval for Takeda’s schizophrenia drug

EU approval for Takeda’s schizophrenia drug

Takeda and development partner Dainippon Sumitomo Pharma have won European approval for their schizophrenia treatment Latuda (lurasidone).

Latest news

  • GSK's diabetes drug among CHMP recommendations GSK's diabetes drug among CHMP recommendations

    2013. Takeda's antipsychotic and Linepharma's Hemoprostol. Elsewhere in the CHMP opinions, Takeda received a recommendation for the use of Latuda (lurasidone) in the treatment of adults with schizophrenia.

  • Schizophrenia treatments

    Lurasidone, an antagonist of dopamine D2, serotonin 2A, serotonin 7, serotonin 2C and a partial agonist of serotonin 1A, is being marketed by Sunovion Pharmaceuticals.

  • Coronary conundrums

    US. Lurasidone. Latuda (Sunovion Pharmaceuticals). Schizophrenia. US an Puerto Rico. Paracetamol.

  • DSP buys Sepracor

    The move comes as DSP prepares to launch its schizophrenia drug lurasidone, which last month significantly outperformed placebo in late-stage trials. ... The acquisition gives DSP the sales and marketing infrastructure in the US it needs to commercialise

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    There's prostate cancer drug orteronel (TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... From among its product pipeline Smith picks prostate cancer drug orteronel (TAK-700),

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics